RAD-x continues German expansion - Gilde Healthcare

RAD-x continues German expansion

April 17, 2018

Utrecht, The Netherlands – Gilde Healthcare portfolio company RAD-x, the pan-European operator in diagnostic imaging, has announced that it has acquired Teleradiologisches Zentrum Koblenz (TelradKo). TelradKo provides teleradiology services to hospitals and hospital-based imaging centres in Germany. The combination with RAD-x enables TelradKo to accelerate its expansion and continue investing in the latest technology to establish itself as the leading provider of teleradiology services to small and medium sized hospitals.

 

About RAD-x

RAD-x is a fast-growing pan-European operator of diagnostic imaging centres, based on a network of local and regional centres. The network currently has a staff of over 350 healthcare professionals working in diagnostic imaging centres and hospitals. RAD-x’s growth model is based on the integration in its network of existing leading local and regional medical imaging centres and offering their radiologists to become shareholders of RAD-x. For more information, visit the company’s website at www.RAD-x.eu

About TelradKo

TelradKo is a provider of teleradiology services to hospitals and hospital-based imaging centres in Germany founded in 2014. For more information, visit the company’s website at www.telradko.de

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and Dach-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support...
November 25, 2024

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual...
November 14, 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
October 30, 2024